Document Detail

The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis.
MedLine Citation:
PMID:  16396697     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To determine whether it may be successful to try another TNF-alpha antagonist (infliximab or etanercept) when one has failed due to non response or the development of side effects. METHODS: In a cohort of 282 patients with rheumatoid arthritis treated with infliximab or etanercept, we observed 38 patients who had received both agents. RESULTS: Twenty-four patients received infliximab first and 14 received etanercept first. Discontinuation was due to a lack of efficiency for 29 patients and to the occurence of an adverse effect for 9 patients. For 25 out of the 38 patients, the switch was a success according to the global physician's assessment 3 months after switching. This result was correlated to a significant decrease of DAS 28 measurements and CRP values (p < 0.05). The response after switching was recorded as a success for 18 out of the 24 patients who were treated with infliximab first, and for 12 out of the 14 patients who were treated with etanercept first. There was no statistical difference concerning the response after the switch between the two groups. Among the 29 patients who discontinued the first anti TNF-alpha treatment due to lack of efficiency, only 6 did not respond to the second anti TNF-alpha treatment. Only one out of the 9 patients who stopped a first anti TNF-alpha treatment after developing a side effect underwent an adverse event with the second anti TNF-alpha treatment. CONCLUSION: Our study suggests that switching between TNF-alpha antagonists seems to be relevant, regardless of which one was used first. It is legitimate to try to switch TNF-alpha blockers before contemplating other therapeutic strategies.
G Cohen; N Courvoisier; J D Cohen; S Zaltni; J Sany; B Combe
Related Documents :
7539207 - Implication of cytokines in the aggravation of malnutrition and hypercatabolism in elde...
10667507 - Lipopolysaccharide binding protein in acute pancreatitis.
12576957 - Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants re...
20498147 - Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for...
11745287 - Phase ii study of carboplatin and liposomal doxorubicin in patients with recurrent squa...
527617 - Circulating tissue thromboplastin during hip surgery.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  23     ISSN:  0392-856X     ISO Abbreviation:  Clin. Exp. Rheumatol.     Publication Date:    2005 Nov-Dec
Date Detail:
Created Date:  2006-01-10     Completed Date:  2006-02-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  795-800     Citation Subset:  IM    
Service d'Immuno-Rhumatologie, Faculté de Médecine Montpellier I, Centre Hospitalier Universitaire Lapeyronie, Montpellier, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / administration & dosage*,  adverse effects
Antirheumatic Agents / administration & dosage*,  adverse effects
Arthritis, Rheumatoid / drug therapy*
Cohort Studies
Immunoglobulin G / administration & dosage*,  adverse effects
Middle Aged
Receptors, Tumor Necrosis Factor / administration & dosage*
Retrospective Studies
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 185243-69-0/TNFR-Fc fusion protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nailfold capillaroscopic findings in primary Sjögren's syndrome: clinical and serological correlatio...
Next Document:  Survey of Raynaud's phenomenon and systemic sclerosis based on a representative study of 10,000 sout...